Aspirin reduces platelet aggregation during high-energy excimer laser
Ruiping Huang1, Roshan B Patel, Hongbao Ma
1Division of Cardiology, Department of Medicine, Michigan State, University, East Lansing, Michigan 48824, USA.
Lasers in Surgery and Medicine
|September 12, 2006
Summary
Aspirin significantly reduces large platelet aggregates during excimer laser arterial revascularization. This finding suggests aspirin may improve outcomes for patients undergoing this high-energy laser procedure.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
- Hematology
Background:
- Excimer laser technology is utilized in clinical arterial revascularization.
- Platelet aggregation is a critical factor in vascular procedures and thrombotic events.
Purpose of the Study:
- To assess the effectiveness of aspirin in mitigating platelet aggregation induced by high-energy excimer laser exposure.
- To investigate the impact of aspirin on platelet morphology and volume following laser irradiation.
Main Methods:
- Platelet-rich plasma from rabbits was subjected to excimer laser irradiation (308 nm) in the presence and absence of aspirin.
- Platelet aggregation was quantified using laser-light scattering to measure particle volume.
- Platelet morphology was examined using phase contrast and electron microscopy.
Main Results:
- Excimer laser irradiation significantly increased platelet volume in the control group (102.2 ± 18.5 µm³).
- Aspirin treatment markedly reduced platelet volume post-lasing to 43.1 ± 49.2 µm³ (P < 0.0001).
- Aspirin demonstrated a 58% reduction in large platelet aggregates, while small aggregates remained unaffected.
Conclusions:
- Aspirin effectively inhibits the formation of large platelet aggregates during excimer laser treatment of platelet-rich plasma.
- These findings indicate a potential role for aspirin in managing platelet activation and aggregation during arterial revascularization procedures.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.